A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors

被引：12

作者：

Bendell, Johanna C. ^{[1
]}

Jones, Suzanne F. ^{[2
]}

Hart, Lowell ^{[3
]}

Pant, Shubham ^{[4
]}

Moyhuddin, Adil ^{[5
]}

Lane, Cassie M. ^{[2
]}

Earwood, Chris ^{[2
]}

Murphy, Patrick ^{[5
]}

Patton, Jeffrey ^{[5
]}

Penley, William C. ^{[5
]}

Thompson, Dana ^{[5
]}

Infante, Jeffrey R. ^{[5
]}

机构：

[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN 37203 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] SCRI, Florida Canc Specialists, Ft Myers, FL USA

[4] Univ Oklahoma, SCRI, Oklahoma City, OK USA

[5] PLLC SCRI, Tennessee Oncol, Nashville, TN USA

来源：

CANCER INVESTIGATION | 2015年 / 33卷 / 10期

关键词：

Hsp90; AUY922; Capecitabine; 17-DEMETHOXYGELDANAMYCIN; PHARMACOKINETICS; 17-ALLYLAMINO; TANESPIMYCIN; COMBINATION; SAFETY;

D O I：

10.3109/07357907.2015.1069834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: This phase I study determined the maximum tolerated dose (MTD) of AUY922 with capecitabine in advanced solid tumors. Methods: Capecitabine 1000mg/m(2) PO BID was administered with escalating doses of AUY922 IV; the MTD of AUY922 was combined with capecitabine 1250mg/m(2) (DL6). Results: 23 patients were treated at 5 dose levels (22mg/m(2)-70mg/m(2)). No DLTs were observed until DL6 (grade 3 diarrhea). Reversible vision darkening was seen in 26%. Four patients had partial response; 2 previously progressed on fluorouracil. Eight patients had stable disease (median 25.5 weeks). Conclusion: AUY922 plus capecitabine was well-tolerated up to 70mg/m(2) with encouraging preliminary efficacy.

引用

页码：477 / 482

页数：6

共 14 条

[1] Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies [J].

Banerji, U ;

O'Donnell, A ;

Scurr, M ;

Pacey, S ;

Stapleton, S ;

Asad, Y ;

Simmons, L ;

Maloney, A ;

Raynaud, F ;

Campbell, M ;

Walton, M ;

Lakhani, S ;

Kaye, S ;

Workman, P ;

Judson, I .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) :4152-4161

[2]

Bauer T, 2013, IN J CLIN ONCOL S, V31

[3]

Beeram M, 2008, J CLIN ONCOL, V26

[4] Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition [J].

Burkitt, Michael ;

Magee, Conor ;

O'Connor, David ;

Campbell, Fiona ;

Cornford, Philip ;

Greenhalf, William .

MOLECULAR CARCINOGENESIS, 2007, 46 (06) :466-475

[5]

Drysdale MJ, 2006, CURR OPIN DRUG DISC, V9, P483

[6] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[7] A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies [J].

Goldman, Jonathan W. ;

Raju, Robert N. ;

Gordon, Gregory A. ;

El-Hariry, Iman ;

Teofilivici, Florentina ;

Vukovic, Vojo M. ;

Bradley, Robert ;

Karol, Michael D. ;

Chen, Yu ;

Guo, Wei ;

Inoue, Takayo ;

Rosen, Lee S. .

BMC CANCER, 2013, 13

[8]

Johnson M, 2013, IN J CLIN ONCOL S, V31

[9] Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? [J].

Neckers, Len ;

Workman, Paul .

CLINICAL CANCER RESEARCH, 2012, 18 (01) :64-76

[10] Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer [J].

Ono, Naomi ;

Yamazaki, Toshikazu ;

Tsukaguchi, Toshiyuki ;

Fujii, Toshihiko ;

Sakata, Kiyoaki ;

Suda, Atsushi ;

Tsukuda, Takuo ;

Mio, Toshiyuki ;

Ishii, Nobuya ;

Kondoh, Osamu ;

Aoki, Yuko .

CANCER SCIENCE, 2013, 104 (10) :1346-1352

← 1 2 →